Influence of the anti‐oestrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer: A systematic review

Author:

Marina Djordje1ORCID,Rasmussen Åse Krogh1,Buch‐Larsen Kristian1,Gillberg Linn12,Andersson Michael3,Schwarz Peter14

Affiliation:

1. Department of Endocrinology and Metabolism, Rigshospitalet Copenhagen Denmark

2. Department of Biomedical Sciences, Center for Healthy Aging Copenhagen University of Copenhagen Copenhagen Denmark

3. Department of Oncology, Centre for Cancer and Organ Diseases, Rigshospitalet Copenhagen Denmark

4. Faculty og Health and Medical Sciences University of Copenhagen Copenhagen Denmark

Abstract

AbstractIntroductionBreast cancer (BC) is a common type of cancer in women. Advances in therapy options have resulted in higher overall survival rates but side effects of cancer treatment are increasingly in the spotlight. The beneficial effects of anti‐oestrogen therapy with tamoxifen and letrozole in the prevention of BC recurrence are well documented. While the most common side‐effects of this therapy are well‐defined, less is known about its effects on thyroid function. In women treated for early BC, an average of 1–5 kg weight gain has been observed after treatment with chemotherapy/anti‐oestrogens. We aim to evaluate the current knowledge on the side effects of tamoxifen and letrozole treatments on thyroid function, followed by its potential influence on the observed weight gain.MethodsWe searched PubMed and found 16 publications on thyroid function and tamoxifen treatment in pre‐ and post‐menopausal women with early‐ and advanced BC, whereas five publications on letrozole treatment in post‐menopausal women with advanced BC.ResultsAccording to the current literature, there is an overall tendency towards a mild and transient thyroid dysfunction, that is, subclinical hypothyroidism in tamoxifen‐treated patients. Only one publication reported further significant changes in thyroid hormones beyond one year of tamoxifen treatment. No significant changes in thyroid function have been observed among letrozole‐treated patients.ConclusionTamoxifen‐treated patients can develop mild and transient thyroid dysfunction within the first 12 months, yet further significant changes in thyroid function beyond one year of tamoxifen treatment have been reported in a single study. There is no evidence of thyroid dysfunction in letrozole‐treated patients. Current literature does not focus on subclinical hypothyroidism as a possible cause of weight gain in patients with BC. Subgrouping of BC patients and studies with a longer observation of thyroid hormones and weight changes during and after anti‐oestrogen treatment are needed to further elucidate how anti‐oestrogens affect thyroid function.

Funder

Novo Nordisk Fonden

Publisher

Wiley

Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.7亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2025 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3